Elicera Therapeutics announced on Tuesday that the twelfth and final patient has been treated in the phase I part of the Carma study, which is underway at Uppsala University Hospital and Karolinska University Hospital in Huddinge and evaluates the CAR‑T cell therapy ELC‑301 in recurrent or hard‑to‑treat B‑cell lymphoma.
Elicera reports strong CAR‑T-Data – shares rise
The Swedish CAR‑T developer Elicera saw its share price surge following an update on the company’s ongoing lymphoma study.
Advertisement
BREAKING